Neurim Pharmaceuticals Ltd.

Privately held: no public share price · Israel

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
0Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Melatonin receptor (MT1/MT2)
Indication not yet linked

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.